IN DEVELOPMENT
DUR-928
An endogenous, orally bioavailable small molecule in development for chronic liver disease and acute organ injury.
LEARN MORE
POSIMIR®
(SABER®-Bupivacaine)
An investigational non-opioid, locally-acting analgesic being evaluated for its ability to deliver 3 days of continuous pain relief after surgery.
LEARN MORE
REMOXY® (ORADUR®-Oxycodone) ER capsules
An investigational drug candidate containing oxycodone in extended-release capsules, whose ability to deter common methods of abuse is under study. Oxycodone exposes users to risks of addiction, abuse, and misuse even where abuse-deterrent properties exist. REMOXY ER is not currently authorized by the FDA for marketing in the U.S. for any indication.
LEARN MORE
ORADUR®-Hydromorphone and
ORADUR®-Oxymorphone
Investigational long-acting formulations of hydromorphone and oxymorphone utilizing DURECT’s proprietary abuse-deterrent technology. Hydromorphone and oxymorphone expose users to risks of addiction, abuse, and misuse even where abuse-deterrent properties exist. ORADUR-Hydromorphone and ORADUR-Oxymorphone are not currently authorized by the FDA for marketing in the U.S. for any indication.
LEARN MORE
ORADUR®-Methylphenidate
An investigational once-daily formulation of the widely-prescribed ADHD medication methylphenidate whose ability to resist common methods of tampering is under study.
LEARN MORE
Relday®
(SABER®-Risperidone)
A proprietary injectable form of the antipsychotic medication risperidone based on DURECT’s SABER technology, under evaluation for once-monthly administration.
LEARN MORE
ELADUR®
(TRANSDUR®-Bupivacaine)
A proprietary long-acting transdermal patch in development for the treatment of pain associated with post-herpetic neuralgia.
LEARN MORE
Sustained-release Ophthalmology Product
An investigational sustained-release ophthalmology product incorporating DURECT’s SABER depot technology.
LEARN MORE